These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

436 related items for PubMed ID: 17261600

  • 1. Bradyzoite-specific surface antigen SRS9 plays a role in maintaining Toxoplasma gondii persistence in the brain and in host control of parasite replication in the intestine.
    Kim SK, Karasov A, Boothroyd JC.
    Infect Immun; 2007 Apr; 75(4):1626-34. PubMed ID: 17261600
    [Abstract] [Full Text] [Related]

  • 2. Stage-specific expression of surface antigens by Toxoplasma gondii as a mechanism to facilitate parasite persistence.
    Kim SK, Boothroyd JC.
    J Immunol; 2005 Jun 15; 174(12):8038-48. PubMed ID: 15944311
    [Abstract] [Full Text] [Related]

  • 3. A cluster of four surface antigen genes specifically expressed in bradyzoites, SAG2CDXY, plays an important role in Toxoplasma gondii persistence.
    Saeij JP, Arrizabalaga G, Boothroyd JC.
    Infect Immun; 2008 Jun 15; 76(6):2402-10. PubMed ID: 18347037
    [Abstract] [Full Text] [Related]

  • 4. Detection of the initial site of Toxoplasma gondii reactivation in brain tissue.
    Takashima Y, Suzuki K, Xuan X, Nishikawa Y, Unno A, Kitoh K.
    Int J Parasitol; 2008 Apr 15; 38(5):601-7. PubMed ID: 18022177
    [Abstract] [Full Text] [Related]

  • 5. DNA vaccine encoding the Toxoplasma gondii bradyzoite-specific surface antigens SAG2CDX protect BALB/c mice against type II parasite infection.
    Zhang M, Zhao L, Song J, Li Y, Zhao Q, He S, Cong H.
    Vaccine; 2013 Sep 23; 31(41):4536-40. PubMed ID: 23933373
    [Abstract] [Full Text] [Related]

  • 6. Use of molecular and ultrastructural markers to evaluate stage conversion of Toxoplasma gondii in both the intermediate and definitive host.
    Ferguson DJ.
    Int J Parasitol; 2004 Mar 09; 34(3):347-60. PubMed ID: 15003495
    [Abstract] [Full Text] [Related]

  • 7. Determination of stage interconversion in vitro and in vivo by construction of transgenic Toxoplasma gondii that stably express stage-specific fluorescent proteins.
    Zhang H, Zhang Y, Cao J, Zhou Y, Wang N, Zhou J.
    Exp Parasitol; 2013 Jul 09; 134(3):275-80. PubMed ID: 23545429
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Toxoplasma gondii: determination of the onset of chronic infection in mice and the in vitro reactivation of brain cysts.
    Chew WK, Wah MJ, Ambu S, Segarra I.
    Exp Parasitol; 2012 Jan 09; 130(1):22-5. PubMed ID: 22027550
    [Abstract] [Full Text] [Related]

  • 11. Real-time RT-PCR on SAG1 and BAG1 gene expression during stage conversion in immunosuppressed mice infected with Toxoplasma gondii Tehran strain.
    Selseleh M, Modarressi MH, Mohebali M, Shojaee S, Eshragian MR, Selseleh M, Azizi E, Keshavarz H.
    Korean J Parasitol; 2012 Sep 09; 50(3):199-205. PubMed ID: 22949746
    [Abstract] [Full Text] [Related]

  • 12. Toxoplasma gondii: Simple duplex RT-PCR assay for detecting SAG1 and BAG1 genes during stage conversion in immunosuppressed mice.
    Mahittikorn A, Wickert H, Sukthana Y.
    Exp Parasitol; 2010 Feb 09; 124(2):225-31. PubMed ID: 19854173
    [Abstract] [Full Text] [Related]

  • 13. The timing of sulfadiazine therapy impacts the reactivation of latent Toxoplasma infection in IRF-8-/- mice.
    Jost C, Reiter-Owona I, Liesenfeld O.
    Parasitol Res; 2007 Nov 09; 101(6):1603-9. PubMed ID: 17846793
    [Abstract] [Full Text] [Related]

  • 14. An unexpected response to vaccination with a purified major membrane tachyzoite antigen (P30) of Toxoplasma gondii.
    Kasper LH, Currie KM, Bradley MS.
    J Immunol; 1985 May 09; 134(5):3426-31. PubMed ID: 3884710
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of inducible nitric oxide synthase exacerbates chronic cerebral toxoplasmosis in Toxoplasma gondii-susceptible C57BL/6 mice but does not reactivate the latent disease in T. gondii-resistant BALB/c mice.
    Schlüter D, Deckert-Schlüter M, Lorenz E, Meyer T, Röllinghoff M, Bogdan C.
    J Immunol; 1999 Mar 15; 162(6):3512-8. PubMed ID: 10092808
    [Abstract] [Full Text] [Related]

  • 16. Toxoplasma gondii: DNA vaccination with bradyzoite antigens induces protective immunity in mice against oral infection with parasite cysts.
    Nielsen HV, Di Cristina M, Beghetto E, Spadoni A, Petersen E, Gargano N.
    Exp Parasitol; 2006 Apr 15; 112(4):274-9. PubMed ID: 16368092
    [Abstract] [Full Text] [Related]

  • 17. Antibodies to Toxoplasma gondii major surface protein (SAG-1, P30) inhibit infection of host cells and are produced in murine intestine after peroral infection.
    Mineo JR, McLeod R, Mack D, Smith J, Khan IA, Ely KH, Kasper LH.
    J Immunol; 1993 May 01; 150(9):3951-64. PubMed ID: 7682587
    [Abstract] [Full Text] [Related]

  • 18. Toxoplasma gondii metacaspase 2 is an important factor that influences bradyzoite formation in the Pru strain.
    Song X, Lin M, Li M, Yang X, Liu J, Liu Q.
    Parasitol Res; 2020 Jul 01; 119(7):2287-2298. PubMed ID: 32468190
    [Abstract] [Full Text] [Related]

  • 19. The GRA17 Parasitophorous Vacuole Membrane Permeability Pore Contributes to Bradyzoite Viability.
    Paredes-Santos T, Wang Y, Waldman B, Lourido S, Saeij JP.
    Front Cell Infect Microbiol; 2019 Jul 01; 9():321. PubMed ID: 31572690
    [Abstract] [Full Text] [Related]

  • 20. The BSR4 protein is up-regulated in Toxoplasma gondii bradyzoites, however the dominant surface antigen recognised by the P36 monoclonal antibody is SRS9.
    Van TT, Kim SK, Camps M, Boothroyd JC, Knoll LJ.
    Int J Parasitol; 2007 Jul 01; 37(8-9):877-85. PubMed ID: 17368655
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.